Otter Health Raises $8M to Rethink Prior Authorisation

Otter Health has launched with $8 million to build an AI platform that monitors clinical decision quality continuously rather than relying only on traditional prior-authorisation checkpoints.

What happened

The seed round was co-led by Fika Ventures and Evidenced, with participation from Slow Ventures, Metrodora, CoFound Partners, Layout Ventures, Patient Capital and Semper Virens. Otter compares care decisions against clinical evidence in real time and is designed to help payers and providers manage utilisation. The company says early deployments have allowed some organisations to remove prior authorisation in selected areas while keeping non-concordant clinical decisions below 5%. That result is company-reported and not independently validated.

Why it matters

Traditional prior authorisation can delay care and create large administrative burdens for clinicians and patients. If quality can be monitored continuously rather than at a single approval gate, payers may be able to reduce friction while still managing inappropriate or unnecessary care.

The bigger picture

The approach is more ambitious than simply automating prior-authorisation forms. Otter is trying to redesign the control mechanism itself. Success will depend on clinical accuracy, transparency, payer trust and evidence that the system improves access without increasing unnecessary spending.